Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?

被引:0
|
作者
Sedky, Mohamed [1 ,2 ]
Gohar, Seham [1 ]
Ahmed, Sonia [1 ,3 ]
Zaky, Iman [4 ,5 ]
Salama, Asmaa [6 ,7 ]
Hassanein, Omayma [8 ]
Maher, Eslam [8 ]
Elhaddad, Alaa [1 ,3 ]
机构
[1] Children Canc Hosp Egypt 57357 1, Dept Pediat Oncol, Sekket Al Imam St, Cairo 11617, Egypt
[2] Natl Res Ctr, Dept Pediat, Cairo, Egypt
[3] Cairo Univ, Natl Canc Inst, Dept Pediat Oncol, Cairo, Egypt
[4] Children Canc Hosp Egypt 57357, Dept Radiol, Cairo 11617, Egypt
[5] Cairo Univ, Natl Canc Inst, Dept Radiol, Cairo, Egypt
[6] Childrens Canc Hosp 57357, Dept Pathol, Cairo 11617, Egypt
[7] Cairo Univ, Natl Canc Inst, Dept Pathol, Cairo, Egypt
[8] Childrens Canc Hosp 57357, Dept Clin Res, Cairo 11617, Egypt
关键词
Pulmonary; LCH; Multisystem; Survival; RO-; RO plus; Lung lesions; Severity; CHILDREN; DISEASE; INVOLVEMENT; DIAGNOSIS; EVOLUTION; THERAPY;
D O I
10.1186/s13023-023-02970-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background The pediatric pulmonary multisystem Langerhans cell histiocytosis (PPM LCH) is associated with either low risk or high risk organ(s). The nodulo-cystic lung lesions although pathognomonic, yet are very variable in severity and remain a source of controversy in certifying pulmonary LCH diagnosis. The study aimed to examine the prognostic value of clinical respiratory manifestations and radiological lung lesions severity. This is through associating a CT chest triad of bilateral, extensive and diffuse lesions. It is a retrospective study of 350 LCH patients who received systemic treatment at Children's Cancer Hospital Egypt during the period from 2007 to 2020.Results Sixty-seven patients (67/350-19.1%) had PPM LCH at presentation. Severe lung lesions were present in 24 of them. The median follow-up period was 61 months (IQR: 3.4-8.3). The 5-year overall survival (OS) and event free survival (EFS) was 89% and 56.6% respectively. The EFS, for severe radiological lesions triad was 38% +/- 20.7 versus 66% +/- 16.2 for non-severe lesions triad p 0.002, while for presence of chest X-ray changes 27% +/- 22.344 versus absence of chest X ray changes 66% +/- 14.7 p 0.001, for clinical respiratory manifestations 13% +/- 13.9 versus none 62% +/- 22.9 p < 0.001, for RO- with severe lung lesions 47% +/- 30.4 versus RO- without severe lung lesions 69% +/- 5.9 p 0.04. There was a tendency for the independent prognostic impact of severe lung involvement; aHR = 1.7 (95% CI 0.92-3.13, p = 0.09).Conclusion Although the lung is a low -risk organ per se in LCH, our study demonstrates a non negligeable prognostic impact of severe lung involvement in the risk stratification of pediatric LCH. This warrants further study and external validation.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Pulmonary Langerhans Cell Histiocytosis: Case Series and Literature Review
    Wei, Ping
    Lu, Hai-Wen
    Jiang, Sen
    Fan, Li-Chao
    Li, Hui-Ping
    Xu, Jin-Fu
    MEDICINE, 2014, 93 (23)
  • [22] Infiltrating the Heart and Kidney: A Rare Pediatric Case of Multisystem Langerhans Cell Histiocytosis from Pakistan
    Mahmood, Samar
    Raza, Mohammad
    Nusrat, Khushboo
    Marsia, Shayan
    Abbas, Awais
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (03)
  • [23] Combination of Neoadjuvant Therapy and Liver Transplantation in Pediatric Multisystem Langerhans Cell Histiocytosis With Liver Involvement
    Chen, Chen
    Gu, Guangxiang
    Zhou, Tao
    Huang, Mingzhu
    Xia, Qiang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis
    Minkov, Milen
    Poetschger, Ulrike
    Thacker, Nirav
    Astigarraga, Itziar
    Braier, Jorge
    Donadieu, Jean
    Henter, Jan-Inge
    Lehrnbecher, Thomas
    Rodriguez-Galindo, Carlos
    Sieni, Elena
    Nanduri, Vasanta
    van den Bos, Cor
    Abla, Oussama
    JOURNAL OF PEDIATRICS, 2021, 237 : 65 - +
  • [25] Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib
    Trambusti, Irene
    Pegoraro, Francesco
    Gaspari, Stefania
    Dell'Acqua, Fabiola
    Cellini, Monica
    Trizzino, Antonino
    Tondo, Annalisa
    Perrone, Anna
    Coniglio, Maria Luisa
    Guerrini, Renzo
    Barba, Carmen
    Sieni, Elena
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (06) : 2508 - 2511
  • [26] Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung
    Kalchiem-Dekel, Or
    Paulk, Adina
    Kligerman, Seth J.
    Burke, Allen P.
    Shah, Nirav G.
    Dixon, Renee K.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (12) : E1079 - E1083
  • [27] Growth and Endocrinal Abnormalities in Pediatric Langerhans Cell Histiocytosis
    Dabas, Aashima
    Batra, Atul
    Khadgawat, Rajesh
    Jyotsna, Viveka P.
    Bakhshi, Sameer
    INDIAN JOURNAL OF PEDIATRICS, 2016, 83 (07) : 657 - 660
  • [28] Pulmonary Langerhans cell histiocytosis in adults
    Feuillet, Severine
    Giroux-Leprieur, Benedicte
    Tazi, Abdellatif
    PRESSE MEDICALE, 2010, 39 (01): : 107 - 115
  • [29] Adult Langerhans' cell histiocytosis with multisystem involvement A case report
    Kim, Seung Soo
    Hong, Soon Auck
    Shin, Hyeong Cheol
    Hwang, Jeong Ah
    Jou, Sung Shick
    Choi, Seo-Youn
    MEDICINE, 2018, 97 (48)
  • [30] Clinical characteristics and outcome of pediatric patients diagnosed with Langerhans cell histiocytosis in pediatric hematology and oncology centers in Poland
    Anna Raciborska
    Katarzyna Bilska
    Jadwiga Węcławek-Tompol
    Olga Gryniewicz-Kwiatkowska
    Małgorzata Hnatko-Kołacz
    Joanna Stefanowicz
    Anna Pieczonka
    Katarzyna Jankowska
    Filip Pierelejewski
    Tomasz Ociepa
    Grażyna Sobol-Milejska
    Katarzyna Muszyńska-Rosłan
    Olga Michoń
    Wanda Badowska
    Monika Radwańska
    Katarzyna Drabko
    BMC Cancer, 20